Anti-NMDA Receptor Encephalitis in a Pregnant Woman

Jiyoung Kim, Seung Ha Park, Yu Ri Jung, Soon Won Park, Dae Soo Jung
Department of Neurology, Pusan National University Hospital and Pusan National University School of Medicine, and BioMedical Research Institute, Pusan National University Hospital, Busan, Korea

Case Report
Journal of Epilepsy Research
pISSN 2233-6249 / eISSN 2233-6257

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is one of the most common types of autoimmune synaptic encephalitis. Anti-NMDA receptor encephalitis commonly occurs in young women with ovarian teratoma. It has variable clinical manifestations and treatment responses. Sometimes it is misdiagnosed as a psychiatric disorder or viral encephalitis. To the best of our knowledge, anti-NMDA receptor encephalitis is a rare condition in pregnant women. We report a case of anti-NMDA receptor encephalitis in a pregnant woman who presented with abnormal behavior, epileptic seizure, and hypoventilation. (2015;5:29-32)

Key words: NMDA receptor antibodies, Ovarian teratoma, Pregnancy, Outcome

Introduction

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis was first reported in 2005 in four patients with ovarian teratoma.1 Many cases of anti-NMDAR encephalitis have been reported since the antigen (Ag) for the NMDAR Antibody (Ab) was confirmed in 2007.2 It is a type of autoimmune synaptic encephalitis. While the pathophysiology is not completely understood, it is known that the NMDAR Ab is principally associated with the antibody against NR1 subunit of the NMDA receptors.3 The patient with anti-NMDAR encephalitis develops fever, headache, abnormal behavior, memory loss, autonomic dysfunction, seizure, hypoventilation, and dyskinesia. Sometimes the patient is misdiagnosed as having schizophrenia because of behavioral disturbance.4 Lim et al. reported that, in Korea, the most frequently presented symptoms of patients were psychiatric (68.8%) followed by epileptic seizure (50.0%).5 Although anti-NMDAR encephalitis can occur in females or males, it frequently occurs in women with ovarian teratoma.6 However, to the best of our knowledge, anti NMDAR encephalitis is a rare condition in pregnant women. We report a case of anti NMDAR encephalitis in a pregnant woman who presented with abnormal behavior, hypoventilation, and epileptic seizure. Also we give a report long term clinical treatment outcome.

Case

A 28-year-old woman presented with abnormal behavior, hypoventilation, and epileptic seizure. At the time, she was pregnant (gestational age 7 weeks + 4 days). She had mild fever, headache, and sleep disturbance for the previous two weeks. She had neither previous medical history nor medication. An emergency brain computed tomography (CT) scan, brain magnetic resonance imaging (MRI), and a lumbar puncture were performed while the patient was in the emergency room. Emergency CT scan and brain MRI were normal (Fig. 1A). Cerebrospinal fluid (CSF) analysis revealed pressure of 230 mmH2O, 162 white cells per mm3 (92% lymphocytes), 48 mg/dl glucose, 46.2 mg/dl proteins with no organisms on the Gram stain, and negative CSF cultures. We initially considered her symptoms were indicating a viral encephalitis, and empiric therapy with acyclovir (10 mg/Kg/8 hr) was thus initiated. Transabdominal ultrasoundography was performed to evaluate the fetal status in the emergency room. The fetus was healthy; however, we could not detect ovarian teratoma from the transabdominal ultrasonography.

After admission, the patient rapidly developed hypoventilation, epileptic seizure, and dyskinesia, and showed comatose mentality several days later. She was given an anti-epileptic drug (levetiracetam 1,500 mg/day) and mechanical ventilation. During her stay in the intensive care unit (ICU), the fetus miscarried, the cause of which is unclear. After 2 weeks of admission, her autoimmune synaptic antibody test results were reported. Serum and CSF were positive for the anti-NMDAR Ab. We started intravenous methylprednisolone (1,000 mg/day) for 5 days and promptly initiated the 5-day course of intravenous immunoglobulin (0.4 g/Kg/day). After these treatments, we maintained a low dose of oral corticosteroids. We again performed...
transabdominal ultrasonography to detect the ovarian teratoma and informed the sonographer that she may have ovarian teratoma. However, we failed to detect the ovarian teratoma. We performed an abdomen-pelvic CT and it showed right ovarian teratoma (Figs. 2A, B). We removed the ovarian teratoma and performed plasmapheresis six times. However, her comatose mental state did not improve. Epileptic seizures were observed intermittently and ictal electroencephalogram (EEG) was developing from the left frontocentrotemporal area and spreading to the left hemisphere (Figs. 3A, B). Her symptom of hypoventilation persisted and a mechanical ventilator was used continuously. We considered using second-line therapy such as rituximab. However, pneumonia and cerebral salt wasting syndrome could not be controlled, causing a delay of several weeks in starting rituximab. After seven weeks, we started rituximab. Rituximab was administered every week, for 4 weeks (375 mg/m²). From one week after the start of rituximab therapy, her mental status and respiration were improved. From two weeks after the start of rituximab therapy, she was able to obey a one step command and breathe via self respiration without a mechanical ventilator. She was discharged to home after 22 weeks of hospital treatment (Fig. 4), and she regularly visited the outpatient neurological clinics. Follow-up brain MRI was performed at 10 months from the onset of her clinical symptoms. Brain MRI showed diffuse brain atrophy and bilateral hippocampal atrophy on fluid attenuation inversion recovery (FLAIR) images and T2 weighted images (T2WI). (Fig. 1B). However, there was continuous improvement in the cognitive function and the follow-up modified Rankin Scale (mRS) score was 1 at one year from the onset of her symptoms.
Clinical course

- Comatose mentality
- Hypoventilation
- Epileptic seizure
- Abnormal behavior
- Worsened Pneumonia
- Headache
- Fever
- Insomnia
- Plasmapheresis
- Resection of ovarian teratoma
- MPD
- IVIG
- Cerebral salt wasting syndrome
- Rituximab

Figure 4. Clinical course and treatment. A patient presented comatose mentality, hypoventilation, and occasionally epileptic seizure in ICU and was treated with corticosteroid, IVIG, plasmapheresis, and rituximab. ICU, intensive care unit; NMDAR, N-methyl-d-aspartate receptor; MPD, methylprednisolone; IVIG, intravenous immunoglobulin; GW, general ward; mRS, modified Rankin Scale.

Discussion

This is a case report of anti-NMDAR encephalitis in a pregnant woman. We performed transabdominal ultrasonography two times. The first transabdominal ultrasonography was performed to evaluate the fetal status. The second transabdominal ultrasonography was performed to detect the ovarian teratoma. However, we failed to detect the ovarian teratoma using transabdominal ultrasonography. According to research, variable accuracy of diagnostic value on ovarian teratoma using ultrasonogram has been reported. Mais et al. reported a sensitivity of 57.9% and specificity of 99.7% in diagnosing mature cystic teratoma using transvaginal ultrasonography. Patel et al. reported that the combination of transabdominal ultrasonogram and transvaginal ultrasonogram showed 85% sensitivity for the diagnosis and identification of cystic teratoma. Occasionally, ultrasonography is not sufficient to detect ovarian teratoma. In the emergency room, we could not actively use the radiological diagnostic tool because she was pregnant. Also, we did not conduct the abdominal-pelvic MRI in the emergency room. We considered her viral encephalitis and her symptoms had rapidly deteriorated. We did not have sufficient time to perform abdominal-pelvic MRI in the early period of the disease. After two weeks of admission, the NMDAR Ab was found to be positive, and we finally detected ovarian teratoma with the abdominal-pelvic CT after her fetus had miscarried. Late detection of ovarian teratoma delayed her treatment. However, although treatment required a long period of time, her mental status and cognition gradually improved and were nearly normal at the follow-up after one year from the onset of symptoms.

Anti-NMDAR encephalitis in pregnant women has been rarely reported. However, Anti-NMDAR encephalitis in pregnant women has recently been more frequently reported with growing concern about Anti-NMDAR encephalitis. Also, developmental outcomes have more frequently reported that fetuses and babies have been born from mothers with anti-NMDAR encephalitis. Chan et al. reported Anti-NMDAR encephalitis in a pregnant woman who miscarried within 2 days of hospitalization. In another case of Anti-NMDAR encephalitis in a pregnant woman, Jagota et al. reported that the baby showed NMDR antibody titer at the same level as that of the mother 2 days after birth and was negative at 1 year. Also, the baby showed developmental delay and cortical dysplasia in a brain MRI.
is unclear whether the causes of delayed development and cortical
dysplasia are the transfer of maternal antibodies, maternal medi-
cation, or the indirect effect of maternal illness. Lamale-Smith et al.
reported that NMDAR antibodies were capable of maternal-fetal
transfer and reported appropriate development of a baby at one
year.13 Kumar et al. reported three cases of anti-NMDAR encephalitis
in pregnant women.14 These three patients developed symptoms be-
tween 8 and 17 weeks. In one of these patients, who had bilateral
ovarian teratoma and severe neurological complications, the preg-
nancy was terminated. However, two of these patients gave birth to
normal babies. The authors suggested the good outcome of these
two neonates was related to the period of transplacental transfer of
Immunoglobulin G (IgG). IgG1 and G3 cross the placenta by binding
to Fc neonatal receptor present in the syncytiotrophoblast and this
process of placental transfer occurs at around 14 to 16 weeks.15 This
results in a very low level of fetal blood IgG at the time of onset of
clinical symptoms. Additionally, the fetal blood-brain barrier becomes
functional by the end of the second trimester, and this is one of the
reasons for the delivery of a normal baby.

In summary, this case highlighted the importance of active at-
ttempts to detect the ovarian teratoma in pregnant women with an-
ti-NMDAR encephalitis. If pregnancy limits the use of a radiologic di-
agnostic tool such as abdomen-pelvic CT, an abdominal-pelvic MRI
should be performed as early as possible. Transabdominal or trans-
vaginal ultrasonography is not sufficient for detecting ovarian ter-
atoma in some cases. Also, various treatments should be performed.
A long time was needed to recover from the comatose mentality and
restore cognition. Lastly, the clinician should be concerned about the
best way to determine a fetal developmental outcome. Later an-
ti-NMDAR encephalitis in cases of pregnant women may resolve this
issue.

References

1. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation
   in ovarian teratoma. Ann Neurol 2005;58:594-604.
2. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methy-
    l-D-aspartate receptor encephalitis associated with ovarian teratoma.
   Ann Neurol 2007;61:25-36.
3. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-
    Gordon R. Clinical experience and laboratory investigations in patients
   with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.
4. Lee HS, Kim SW, Chung SJ, Yoo HS, Lee PI, Choi SA. Anti-NMDA re-
   ceptor encephalitis which has shown clinical symptoms of schizophrenia.
   J Korean Neurol Assoc 2013;31:115-7.
5. Lim IA, Lee ST, Jung KH, et al. Anti-N-methyl-d-aspartate receptor
   encephalitis in Korea: clinical features, treatment, and outcome. J Clin
   Neurol 2014;10:157-61.
6. Titaule MI, McCracken L, Gabliando I, et al. Treatment and prognostic
   factors for long-term outcome in patients with anti-NMDA receptor
   encephalitis: an observational cohort study. Lancet Neurol 2013;12:
   157-65.
7. Mais V, Guerriero S, Ajossa S, Angiolucci M, Paolotti AM, Melis GB.
   Transvaginal ultrasonography in the diagnosis of cystic teratoma. Obstet
   Gynecol 1995;85:48-52.
8. Patel MD, Feldstein VA, Lipson SD, Chen DC, Filly RA. Cystic teratomas
   of the ovary: diagnostic value of sonography. AJR Am J Roentgenol
   1998;171:1061-5.
9. McCarthy A, Dineen J, McMenam P, et al. Anti-NMDA receptor ence-
   phalitis with associated catatonia during pregnancy. J Neurol 2012;259:
   2632-5.
10. Ito Y, Abe T, Tomioka R, Komori T, Araki N. [Anti-NMDA receptor en-
    cephalitis during pregnancy]. Rinsho Shinkeigaku 2010;50:103-7.
11. Chan LW, Nilsson C, Schepel J, Lynch C. A rare case of anti-N-meth-
    yl-D-aspartate receptor encephalitis during pregnancy. N Z Med J
   2015;128:89-91.
12. Jagota P, Vincent A, Bhidayasiri R. Transplacental transfer of NMDA
   receptor antibodies in an infant with cortical dysplasia. Neurology 2014;
   82:1662-3.
13. Lamale-Smith LM, Moore GS, Gurtupalli SR, Scott JB. Maternal-fetal
   transfer of anti-N-methyl-D-aspartate receptor antibodies. Obstet Gynecol
   2015;125:1056-8.
14. Kumar MA, Jain A, Dechant VE, et al. Anti-N-methyl-D-aspartate re-
   ceptor encephalitis during pregnancy. Arch Neurol 2010;67:884-7.
15. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age.
   Nat Rev Immunol 2007;7:715-25.